Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Validity of at-home rapid antigen lateral flow assay and artificial intelligence read to detect SARS-CoV-2.

Validity of at-home rapid antigen lateral flow assay and artificial intelligence read to detect SARS-CoV-2. Diagnostic microbiology and infectious disease Richardson, S., Kohn, M. A., Bollyky, J., Parsonnet, J. 2022; 104 (3): 115763

Abstract

BACKGROUND: The gold standard for COVID-19 diagnosis-reverse-transcriptase polymerase chain reaction (RT-PCR)- is expensive and often slow to yield results whereas lateral flow tests can lack sensitivity.METHODS: We tested a rapid, lateral flow antigen (LFA) assay with artificial intelligence read (LFAIR) in subjects from COVID-19 treatment trials (N=37; daily tests for 5 days) and from a population-based study (N=88; single test). LFAIR was compared to RT-PCR from same-day samples.RESULTS: Using each participant's first sample, LFAIR showed 86.2% sensitivity (95% CI 73.6%-98.8) and 94.3% specificity (88.8%-99.7%) compared to RT-PCR. Adjusting for days since symptom onset and repeat testing, sensitivity was 97.8% (89.9%-99.5%) on the first symptomatic day and decreased with each additional day. Sensitivity improved with artificial intelligence (AI) read (86.2%) compared to the human eye (71.4%).CONCLUSION: LFAIR showed improved accuracy compared to LFA alone. particularly early in infection.

View details for DOI 10.1016/j.diagmicrobio.2022.115763

View details for PubMedID 36070629